Literature DB >> 8695561

Clinical evaluation of carbocyclic oxetanocin G eyedrops in the treatment of herpes simplex corneal ulcers.

H Shiota1, K Nitta, T Naito, Y Mimura, T Maruyama.   

Abstract

BACKGROUND: Acyclovir (ACV) ophthalmic ointment is effective in the treatment of herpetic keratitis. However, when applied, the ointment has an unpleasant feeling and some cases are resistant to ACV. A new antiviral compound, carbocyclic oxetanocin G (C.OXT-G) has potent anti-herpes simplex virus activity and high water solubility, so the clinical effect of C.OXT-G eyedrops on ulcerative herpetic keratitis was evaluated.
METHODS: Studies were conducted on the corneal ulcers in 37 eyes of 27 patients. Patients with typical dendritic or geographic corneal ulcers were treated with 0.1% C.OXT-G eyedrops, applied five times a day, together with eyedrops of an antibiotic applied four times a day. The eyes were examined at least twice a week until the ulcers healed, and thereafter at intervals for up to 3 months.
RESULTS: All of the ulcers healed, their average healing time being 4.9 (SD 2.2) (range 2 to 9) days. The ulcers in 20 of the 37 eyes were induced by the use of corticosteroid or immunosuppressive drugs, and their average healing time was 4.8 (2.3) days. No adverse drug reactions were seen during the observation period in this trial.
CONCLUSION: Eyedrops containing 0.1% C.OXT-G are excellent and safe for treatment of herpes simplex corneal ulcers in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695561      PMCID: PMC505491          DOI: 10.1136/bjo.80.5.413

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

1.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.

Authors:  H J Schaeffer; L Beauchamp; P de Miranda; G B Elion; D J Bauer; P Collins
Journal:  Nature       Date:  1978-04-13       Impact factor: 49.962

3.  Acyclic antimetabolite therapy of experimental herpes simplex keratitis.

Authors:  D Pavan-Langston; R Campbell; J Lass
Journal:  Am J Ophthalmol       Date:  1978-11       Impact factor: 5.258

4.  Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers.

Authors:  P C Wellings; P N Awdry; F H Bors; B R Jones; D C Brown; H E Kaufman
Journal:  Am J Ophthalmol       Date:  1972-06       Impact factor: 5.258

5.  A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis.

Authors:  D Pavan-Langston; C H Dohlman
Journal:  Am J Ophthalmol       Date:  1972-07       Impact factor: 5.258

6.  Intraocular antiviral penetration.

Authors:  R H Poirier; J D Kingham; P de Miranda; M Annel
Journal:  Arch Ophthalmol       Date:  1982-12

7.  Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers.

Authors:  J McGill; P Tormey; C B Walker
Journal:  Br J Ophthalmol       Date:  1981-09       Impact factor: 4.638

8.  Acyclovir-resistant herpes simplex virus keratouveitis after penetrating keratoplasty.

Authors:  P L Sonkin; K H Baratz; R Frothingham; L M Cobo
Journal:  Ophthalmology       Date:  1992-12       Impact factor: 12.079

9.  Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration.

Authors:  L M Collum; A Benedict-Smith; I B Hillary
Journal:  Br J Ophthalmol       Date:  1980-10       Impact factor: 4.638

10.  Herpetic epithelial keratitis caused by acyclovir-resistant strain.

Authors:  Y Mori; Y Inoue; Y Shimomura
Journal:  Jpn J Ophthalmol       Date:  1994       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.